Current drug treatments targeting enhanced insulin secretion successfully ameliorate the symptoms of T2DM but are ineffective in triggering disease regression because they do not inhibit the pathways causing β-cell loss. This evidence concerns the gene INS and type 2 diabetes mellitus.